M&A Deal Summary

Illumina Acquires GenoLogics Life Sciences Software

On September 1, 2015, Illumina acquired information technology company GenoLogics Life Sciences Software

Acquisition Highlights
  • This is Illumina’s 2nd transaction in the Information Technology sector.
  • This is Illumina’s 9th transaction in the United States.
  • This is Illumina’s 1st transaction in British Columbia.

M&A Deal Summary

Date 2015-09-01
Target GenoLogics Life Sciences Software
Sector Information Technology
Buyer(s) Illumina
Deal Type Add-on Acquisition

Target

GenoLogics Life Sciences Software

Victoria, British Columbia, United States
GenoLogics Life Sciences Software, Inc. is a developer of laboratory information management systems (LIMS) for life sciences organizations.

Search 214,981 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Illumina

San Diego, California, United States

Category Company
Founded 1998
Sector Life Science
Employees10,590
Revenue 4.4B USD (2024)
DESCRIPTION
Entrance to Illumina's corporate headquarters in San Diego, California.
Entrance to Illumina's corporate headquarters in San Diego, California.

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. Illumina was formed in 1998 and is based in San Diego, California.


DEAL STATS #
Overall 10 of 31
Sector: Information Technology M&A 2 of 2
Type: Add-on Acquisition M&A Deals 9 of 14
State: British Columbia M&A 1 of 1
Country: United States M&A 9 of 22
Year: 2015 M&A 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-18 Helix

San Mateo, California, United States

Helix is a population genomics company working at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world’s largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+® assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research. Helix is based in San Mateo, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-26 Conexio Genomics Pty.

Fremantle, Australia

Conexio Genomics Pty. Ltd. is a life sciences company. Conexio develops novel genetic sequencing and mutation detection products and services.

Buy -